In a 15-year-old inpatient who has been taking aripiprazole (Abilify) 15 mg daily and sertraline 100 mg daily, with recent non‑compliance and an attempted aripiprazole overdose, what medication changes are recommended?

Medication Management After Aripiprazole Overdose in an Adolescent

In this 15-year-old with recent non-compliance and an aripiprazole overdose attempt, the immediate priority is ensuring medical stability from the overdose, then reassessing the medication regimen with strong consideration for switching from aripiprazole to an alternative antipsychotic or mood stabilizer, while continuing sertraline with close monitoring for behavioral activation and suicidality.

Immediate Overdose Management

The aripiprazole overdose requires close monitoring despite its relatively favorable safety profile. The FDA label documents that overdoses up to 1,260 mg (42 times the maximum daily dose) have been survived, though this patient took a significant amount 1. Common overdose effects include vomiting, somnolence, and tremor, but serious complications can include seizures, cardiac arrhythmias (QT prolongation, tachycardia), altered consciousness, and respiratory depression 1.

Critical monitoring points:

• Obtain ECG immediately and institute cardiac monitoring if QT prolongation is present 1
• Watch for a biphasic course of somnolence—symptoms may initially improve then worsen again, requiring observation for at least 72 hours 2
• Monitor vital signs, mental status, and watch for extrapyramidal symptoms
• Activated charcoal is only useful if given within 1 hour of ingestion (reduces absorption by 50%) 1

Medication Reassessment Strategy

The Non-Compliance and Overdose Context

The combination of recent non-compliance followed by intentional overdose with the same medication signals several critical issues:

• Access to lethal means: The patient had access to enough aripiprazole to attempt overdose
• Treatment failure: Non-compliance suggests either poor tolerability, lack of efficacy, or inadequate engagement
• Safety concerns: The overdose attempt indicates acute suicidality requiring intensive monitoring 3

Sertraline Considerations

Continue sertraline 100 mg with enhanced monitoring, but be vigilant for:

• Behavioral activation/agitation: SSRIs can cause motor restlessness, impulsiveness, disinhibited behavior, and aggression, particularly in younger adolescents and those with anxiety disorders 3
• Suicidality: The FDA black box warning applies through age 24, with close monitoring essential especially in the first months and after dose changes 3
• Mania/hypomania: Distinguish from behavioral activation—mania typically appears later in treatment and persists after SSRI discontinuation, whereas behavioral activation occurs early and resolves quickly with dose reduction 3

The combination of aripiprazole with sertraline has demonstrated efficacy in depression 4, 5, but the overdose attempt necessitates reconsidering this approach.

Aripiprazole Decision

Strongly consider discontinuing or switching aripiprazole for these reasons:

1. Safety concern: The patient used this medication as the means of overdose attempt—continuing provides ongoing access to lethal means
2. Non-compliance history: Suggests poor tolerability or lack of perceived benefit
3. Alternative options available: Other atypical antipsychotics or mood stabilizers may be better tolerated

If continuing aripiprazole is deemed necessary (e.g., clear prior efficacy, patient/family preference):

• Reduce dose to 5 mg daily (lower starting dose for adolescents per guidelines) 6, 7
• Dispense minimal quantities with strict family control
• Consider long-acting injectable formulation to improve adherence and reduce overdose risk (though this requires patient cooperation)

Recommended Medication Changes

First-line alternative approach:

Switch to risperidone 0.5-2 mg daily or quetiapine 25-50 mg twice daily 8, 6:

• Both have evidence in adolescent populations
• Risperidone: Start 0.5 mg daily, less likely to cause extrapyramidal symptoms at doses <6 mg/day 6
• Quetiapine: Start 25 mg twice daily, more sedating (may help with sleep), less risk of extrapyramidal symptoms 6
• Both available as orally disintegrating tablets to confirm ingestion

Second-line considerations if mood stabilization is primary concern:

Based on the clinical presentation (depression, possible bipolar features given aripiprazole use), consider:

• Lamotrigine: Starting 25 mg daily with slow titration, evidence for bipolar depression in adolescents 9
• Valproate: Starting 125 mg twice daily, evidence in juvenile mania 9
• Lithium: The only FDA-approved mood stabilizer for adolescents ≥12 years, though requires close monitoring 9

Safety Protocol Implementation

Immediate safety measures:

• Restrict access to all medications: Family/staff control of all psychotropics with daily witnessed administration
• Minimize dispensed quantities: No more than 7-day supplies
• Remove other potential means: Assess home safety, remove other medications, sharps, etc.
• Intensive monitoring: Daily to every-other-day contact initially, with clear crisis plan

Monitoring schedule for medication changes:

• Week 1-2: Every 2-3 days contact (phone or in-person)
• Week 3-4: Weekly contact
• Week 6: Formal reassessment of efficacy and tolerability
• Week 12: Full symptom and functional assessment

Common Pitfalls to Avoid

1. Resuming the same regimen without addressing non-compliance: This ignores the treatment failure signal
2. Inadequate overdose observation period: Aripiprazole can cause delayed or biphasic symptoms requiring 72-hour monitoring 2
3. Missing behavioral activation from sertraline: Can be mistaken for worsening depression or emerging mania 3
4. Polypharmacy without clear indication: Avoid adding multiple agents simultaneously—make one change at a time
5. Insufficient family psychoeducation: Families need written information about warning signs, medication effects, and crisis management 3

Diagnostic Clarification Needed

The combination of aripiprazole and sertraline suggests either:

• Treatment-resistant depression (aripiprazole as augmentation)
• Bipolar depression
• Psychotic features
• Behavioral dyscontrol

Reassess the underlying diagnosis while medically stable to guide optimal medication selection. If bipolar disorder is confirmed, antidepressant monotherapy (sertraline alone) carries risk of mood destabilization 9.